{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Number of patients with negative APA"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Number of patients with positive APA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Anti-Product Antibody (APA) concentrations will be measured using validated ELISA methods at the time points specified in the protocol. APA concentrations will be evaluated in the context of pharmacokinetic parameters and AE profiles. Number of patients with positive APA titers on study will be reported.","groups":[{"description":"All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.\n\nTRC105: Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.\n\nBevacizumab: Bevacizumab will be dosed every two weeks.","id":"OG000","title":"TRC105 and/or Bevacizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA).","type":"SECONDARY","unitOfMeasure":"Participants"}